ArticleInternational journal of molecular sciences2026
Serum CA125 for Detection of Antibody-Mediated Rejection in Heart Transplantation Recipients.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although the potential role of carbohydrate antigen 125 (CA125) in acute cellular rejection (ACR) has been explored, its role in antibody-mediated rejection (AMR) remains unclear. Since CA125 is associated with inflammation and congestion, we hypothesized that CA125 could reflect key processes in AMR and complement the existing diagnostic methods. We analyzed 491 serum samples from heart transplant recipients undergoing first-year routine endomyocardial biopsies (EMBs). The results of EMB were classified as no-rejection, ACR, or AMR. CA125 levels were measured using a chemiluminescent immunoassay. CA125 concentrations were significantly higher in the AMR group (median 41 [IQR 26-78] U/mL) than in the no-rejection group (median 17 [IQR 11-27] U/mL;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.